ClinicalTrials.Veeva

Menu
M

Marvel Clinical Research | Huntington Beach, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
ESK-001
Lorundrostat
ACT-541468
MT-7117
fezolinetant
Tanezumab
Ritlecitinib
Dersimelagon
Daridorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 57 total trials

53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

53-Week Study Evaluating the Safety and Efficacy of Intra-articular (IA) Injections of TPX-100 vs Placebo in Subjects with Mild to Severe Tibio-Femor...

Enrolling
Osteoarthritis (OA) of the Knee
Drug: TPX-100 200mg, Once weekly for 4 weeks
Other: PBS

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling
Vitiligo
Drug: Ritlecitinib
Drug: Ritlecitinib 100 mg

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approxi...

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatme...

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep (K-304) Dose level 3

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Enrolling
Epstein-Barr Virus Infection
Biological: Placebo
Biological: mRNA-1195.1

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Active, not recruiting
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Active, not recruiting
NonSegmental Vitiligo
Drug: Povorcitinib
Drug: Placebo

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Active, not recruiting
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.

Enrolling
Non-segmental Vitiligo
Drug: Vehicle Gel
Drug: VYN201 Gel

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling
Dermatitis Atopic
Drug: Placebo
Drug: Amlitelimab

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid E...

Enrolling
Thyroid Eye Disease
Drug: VRDN-003
Drug: Placebo

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid...

Enrolling
Thyroid Eye Disease
Drug: Placebo
Drug: VRDN-003

To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated...

Active, not recruiting
X-Linked Protoporphyria (XLP)
Erythropoietic Protoporphyria (EPP)
Drug: Placebo
Drug: Dersimelagon

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 1-year Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obs...

Active, not recruiting
OSA
Drug: AD109
Drug: Placebo

This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients...

Active, not recruiting
Alzheimer Disease
Drug: MAR

Trial sponsors

Pfizer logo
Incyte logo
Mitsubishi Tanabe Pharma logo
Moderna logo
AbbVie logo
A
Astellas logo
Idorsia Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems